VAIM Successfully Hosts the “JULIA SUMMIT GLOBAL 2025” in Korea

VAIM Successfully Hosts the “JULIA SUMMIT GLOBAL 2025” in Korea

VAIM announced that it successfully hosted the international academic event “JULIA SUMMIT GLOBAL 2025” from November 3 to 5, welcoming medical professionals from more than 30 countries around the world. This summit marks the sixth global edition of JULIA, an academic program—offered both online and offline—designed to share clinical experiences and advanced treatment techniques among physicians using Juvelook.

The three-day summit brought together over 300 medical professionals from Asia, Europe, South America, and the Middle East, including VAIM’s new European distribution partner Fillmed, with whom a strategic partnership was recently established.

Held at Dragon City Seoul in Yongsan, the symposium featured a total of 11 sessions under the theme “The Juvelook Revolution: Science, Practice, Future.” The program included an introduction to the scientific foundation of Juvelook and its MOA video, clinical insights from Korea and Europe, and advanced techniques aimed at enhancing treatment safety. The latest clinical trends in Korea—such as acne scar treatment—were also introduced to international attendees, along with the unveiling of VAIM’s upcoming product lineup, Juvelook i and Juvelook G.

The clinical data presented during the symposium deepened participants’ understanding and highlighted Juvelook’s proven efficacy and emerging treatment potential. Case studies shared by long-term Juvelook users further reinforced the product’s safety and clinical reliability.

As this year’s JULIA SUMMIT GLOBAL 2025 was held in Korea in an expanded format, VAIM provided a diverse range of programs. These included a “Doctor to Doctor” seminar enabling direct exchange of expertise among physicians, a visit to the Seongsu pop-up store JUVE LOOK BOOK HOUSE, and tours of VAIM’s headquarters and Daejeon Factory 2—offering attendees a distinctive and immersive experience.

A VAIM representative stated, “This year’s event received overwhelming interest, with registration exceeding expectations. It was a clear demonstration of the strong trust that international physicians place in the efficacy and safety of Juvelook.” The representative added, “We will continue to strengthen our brand value with scientific evidence and enhance our competitiveness in the global market.”

Introduction of VAIM
Founded in 2014, VAIM is a global medical aesthetics company that develops human tissue regeneration products and improved pharmaceuticals by utilizing its accumulated technology and know-how in biocompatible and biodegradable polymers. It has developed and patented a PDLLA-based manufacturing technology that reduces the risk of nodule formation compared to other ingredient structures, and in 2019, its subsidiary, VAIM, entered the skin booster market with JUVELOOK, which utilizes this technology. JUVELOOK is a collagen booster that induces the production of ECM (collagen, elastin) to provide direct remodeling effects on the skin such as elasticity and wrinkle improvement, and is divided into JUVELOOK and LENISNA depending on the purpose. After quickly proving its safety and effectiveness since its launch, VAIM currently has product export contracts with 72 countries.